Tag:
Targanta Therapeutics
Latest Headlines
Latest Headlines
Medicines Co. withdraws EMEA application for antibiotic
The Medicines Company says it's no longer seeking EMEA approval to market its investigational antibiotic, oritavancin, after the agency indicated that it would need additional data before considering
Medicines Co. snags Targanta for $42M-plus
Antibiotic developer Targanta Therapeutics is being bought out by The Medicines Co. for at least $42 million and a potential bonus based on the regulatory success of oritavancin. The Medicines Co. is
Targanta cuts jobs following FDA rejection
Targanta Therapeutics has decided to pull out the axe following the FDA's rejection of oritavancin, the company's experimental antibiotic for complicated skin and skin structure infections (cSSSI).
Targanta axes 75% of staff
Following the FDA's demand for a new trial of its experimental antibiotic oritavancin, Cambridge, MA-based Targanta is restructuring and cutting 86 employees, or 75 percent of the company's total
Targanta shares need antibiotics
Another company that is taking a hit in the wallet following bad trial news is Targanta Therapeutics. Shares in the company fell 43.6 percent yesterday afternoon and hit a 52-week low earlier in the
FDA: Targanta must conduct new oritavancin study
In a complete response letter the FDA informed Targanta Therapeutics that it will have to conduct another study of oritavancin, the company's experimental antibiotic for complicated skin and skin
FDA backs Theravance antibiotic, rejects Targanta's
Theravance won the crucial backing of an FDA advisory committee for its new antibiotic for serious skin infections. The panel voted 21 to 5 to recommend approval of telavancin, which is also designed
FDA assess two antibiotics up for review
Reviewers for the FDA say that Theravance's experimental antibiotic telavancin was "possibly" related to some of the deaths reported among volunteers taking the drug. In an analysis released today,
